Provision of cellular blood components to CMV‐seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres

Morton, Suzy; Peniket, Andrew; Malladi, Ram; Murphy, Michael

doi:10.1111/tme.12461

Cited by 6 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same is true for the hemoglobin 70 g/L threshold in most instances. In addition, try to reduce synchronous parenteral nutrition (if possible) in patients with excellent transfusion needs [ 17 , 65 , 98 , 104 , 105 , 106 , 107 , 108 , 109 ].…”

Section: Areas Of Particular Interestmentioning

confidence: 99%

See 1 more Smart Citation

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

et al. 2023

View full text Add to dashboard Cite

Transfusion medicine is traditionally a strong/fundamental part of clinical practice, saving hundreds of millions of lives. However, blood-borne or transmitted infections are a well-known and feared possibility, a risk we relentlessly mitigate. Pathogens are continuously and rather quickly changing, so during the last decade, many, sometimes exotic, new pathogens and diseases were recorded and analyzed, and some of them were proved to be transmitted with transfusions. Blood or blood component transfusions are carried out after cautious preparative screening and inactivation maneuvers, but in some instances, newly recognized agents might escape from standard screening and inactivation procedures. Here, we try to focus on some of these proven or potentially pathogenic transfusion-transmitted agents, especially in immunocompromised patients or bone marrow transplantation settings. These pathogens are sometimes new challenges for preparative procedures, and there is a need for more recent, occasionally advanced, screening and inactivation methods to recognize and eliminate the threat a new or well-known pathogen can pose. Pathogen transmission is probably even more critical in hemophiliacs or bone marrow transplant recipients, who receive plasma-derived factor preparations or blood component transfusions regularly and in large quantities, sometimes in severely immunosuppressed conditions. Moreover, it may not be emphasized enough that transfusions and plasma-derived product administrations are essential to medical care. Therefore, blood-borne transmission needs continued alertness and efforts to attain optimal benefits with minimized hazards.

show abstract

Section: Areas Of Particular Interestmentioning

confidence: 99%

“…The administration of allogenic grafts to the recipients confers the risk of infectious and non-infectious disease transmission [ 48 , 98 , 99 , 108 ]. This risk can be minimized by thorough donor testing.…”

Section: Areas Of Particular Interestmentioning

confidence: 99%

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…1 In 2012 the Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) released a position statement on blood components tested for CMV immunoglobulin (Ig)G; for CMV-seronegative patients undergoing HSCT CMV-unselected (CMV-U) leucocyte-reduced components can be safely transfused with no increased risk of transfusion-transmitted CMV infection. 2 According to a recent UK wide survey, nearly 70% of allogeneic stem cell transplant centres in the UK now transfuse CMV-U components to all potential transplant recipients irrespective of serostatus, 3 in line with the SaBTO guidance.…”

Section: Introductionmentioning

confidence: 99%

Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients: A British Society for Haematology Good Practice Paper

et al. 2021

Self Cite

View full text Add to dashboard Cite

The British Society for Haematology (BSH) produces Good-Practice Papers to recommend good practice in areas where there is a limited evidence base but for which a degree of consensus or uniformity is likely to be beneficial to patient care. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) nomenclature was used to evaluate levels of evidence and to assess the strength of recommendations. The GRADE criteria can be found at http:// www.gradeworkinggroup.org.

show abstract

“…13 A survey of UK allogeneic transplant centres reported that nearly 70% of centres transfuse CMV-unselected components regardless of recipient CMV status. 14 In a survey of United States centres, 34Á6% of respondents do not view leucocyte reduction and utilisation of seronegative products as equally effective. Approximately 35% of adult HCT programmes, and 45% of paediatric HCT programmes, transfuse seronegative patients with seronegative products only.…”

mentioning

confidence: 99%

“…Differing transfusion practices, leucocyte reduction methodologies and qualifications among nations are additional confounding variables that may impact the risk of passive antibody transfer 13 . A survey of UK allogeneic transplant centres reported that nearly 70% of centres transfuse CMV‐unselected components regardless of recipient CMV status 14 . In a survey of United States centres, 34·6% of respondents do not view leucocyte reduction and utilisation of seronegative products as equally effective.…”

mentioning

confidence: 99%

Cytomegalovirus immunoglobulin G: passive transfer or prior infection?

2021

View full text Add to dashboard Cite

Provision of cellular blood components to CMV‐seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres

Abstract: The survey demonstrated a surprisingly high rate (22.7%) of centres continuing to provide blood components from CMV-seronegative donors despite SaBTO guidance.

Cited by 6 publications

References 16 publications

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

Transfusion-Transmitted Disorders 2023 with Special Attention to Bone Marrow Transplant Patients

Cytomegalovirus serological testing in potential allogeneic haematopoietic stem cell transplant recipients: A British Society for Haematology Good Practice Paper

Cytomegalovirus immunoglobulin G: passive transfer or prior infection?

Contact Info

Product

Resources

About